

Comparing the Efficacy of add-on Nortriptyline With Triiodothyronine in the Management of Citalopram-Resistant Depression

Naghmeh Mokhber MD^{*}, Ali Talaei MD^{*}

Objective: To manage a treatment resistant depression, clinicians may add a second medication to the first antidepressant drug. The aim of the current research was to study the outcome of augmentation of citalopram with nortriptyline or triiodothyronine in a randomized clinical trial.

Methods: We selected 48 adult outpatients with a diagnosis of non-psychotic major depressive disorder who had not responded to 12 weeks citalopram therapy (40 mg per day). They were randomly allocated to two groups. One group received nortriptyline (at a dose of up to 150 mg per day) and the other triiodothyronine (T3) (at a dose of up to 50 µg per day). The remission of depression was defined as a score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17).

Results: After 8 weeks, the nortriptyline group had a higher remission rate (33.33 %) than the triiodothyronine group (17.64%). The nortriptyline group, however, had a higher dropout rate due to experiencing more side effects.

Conclusion: Augmentation of citalopram with nortriptyline seems to be effective in the management of treatment resistant depression. However, one should strike a balance between the efficacy and the tolerability of this approach, as there is a higher chance of experiencing side effects by the patients.

Iranian Journal of Psychiatry and Behavioral Sciences (IJPBS), Volume 1, Number 1, Spring and Summer 2007 : 23-27.

Keywords: Citalopram • Depression • Nortriptyline • Triiodothyronine

Introduction

The lack of efficacy of an antidepressant in treating at least 20% of depressed patients has prompted the investigators to conduct various research projects to explore other strategies of dealing with treatment resistant depression. One of these strategies is adding an adjunctive agent to pre-existing antidepressant. These can include lithium, sleep deprivation, light therapy, ECT, thyroid hormone (T3) and amisulpride (1,2). Some researchers have shown that to treat a major depressive disorder, clinician often requires more than one medication to achieve a remission (3-10). Frequently, a second medication is added to augment the first drug (6-8). There is evidence to prove the effectiveness of lithium or thyroid hormone in augmenting tricyclic

antidepressants (11,12). These strategies can also be potentially useful in treating patient resistant to serotonin selective reuptake inhibitors (SSRIs) (13,14).

The efficacy of nortriptyline and citalopram has been compared with each other. The remission rate to a therapeutic plasma level of nortriptyline appears to be higher than the remission rate to a standard dose of citalopram, especially in those with endogenous or psychotic features. On the other hand, citalopram appears to be better tolerated (15). However, there are limited data to assess the effect of combination of them in patients with treatment-resistant depression. Furthermore, the choice of treatment after failure of SSRIs in the treatment of depression largely depends on the preferences of the physician. The STARD (Sequenced Treatment Alternatives to Relieve Depression) trials set out to rationalize the treatment of depression after the failure of citalopram. When subjects who were unresponsive or intolerant to citalopram were switched to sustained-release bupropion (14), sertraline or extended-release venlafaxine, remission rates were similar (16).

Authors' affiliation : * Department of Psychiatry Mashad University of Medical Sciences, Iran.

Corresponding author : Naghmeh Mokhber MD, Assistant professor of Psychiatry, Fellowship of neuropsychiatry, Mashad University of Medical Sciences, Avicenna Hospital, Mashad, Iran.
Tel : +98 511 7112701
Fax : +98 511 7112723
E-mail: nmokhber@yahoo.com

Current study compares the efficacy of nortriptyline with triiodothyronine when added to a therapeutic dose of citalopram.

Materials and Methods

Subjects

A total of 48 patients (27 women and 21 men with an age range of 18 to 60) from psychiatric outpatient clinics of two teaching hospitals (Avecina and Ghaem) in Mashhad (Iran) took part in the study in 2005. Seven subjects dropped out of the study due to adverse events (table 1). All patients met DSM-IV criteria for non-psychotic major depression disorder. To enter the study, a patient's thyroid-stimulating hormone (TSH) value had to be within the normal range. Another inclusion criteria was no improvement in depressive symptoms after 8 weeks treatment with 40 mg/day of citalopram.

Table 1. Demographic characteristics of the participants

Characteristics	Both groups N=48	Nortriptyline group N=28	Triiodothyronine group N=20
Age (years \pm SD)	39.8 \pm 18.2	38.2 \pm 18.3	40.18.8 \pm 18.4
Education (years \pm SD)	9.18 \pm 4.4	8.90 \pm 5.3	9.55 \pm 4.9
Male/female (n)	21/27	12/16	9/11
Employment status (n)			
Employed	34	20	14
Non-employed	12	8	4
Retired	2	0	2
Marital status (n)			
Married	38	21	17
Single	1	1	0
Divorced or separated	8	6	2
Widowed	1	0	1
Age at first episode (mean-years) \pm SD	33.43 \pm 15.23	34.37 \pm 15.15	32.65 \pm 11.87
HRSD-17 Scores at study entry (\pm SD)	16.2 \pm 5.40	15.87 \pm 9.18	16.43 \pm 4.23

Exclusion criteria

Subjects with any other DSM-IV diagnosis requiring psychological or pharmacological treatment were excluded from the study. Alcohol and substance dependence or use within 1 month prior to and use of psychotropic medication within 3 months prior to start of the study were other exclusion criteria. Women of childbearing potential who

were without adequate contraception were also excluded from the study.

Informed written consent was obtained from all subjects. The ethics committee of Mashhad University of Medical Sciences (Mashhad, Iran) approved the protocol. The trial was performed in accordance with the declaration of Helsinki.

Assessment and intervention

Subjects (who were already on 40 mg of citalopram) were randomized into two groups. One group (N=28) received nortriptyline (150mg/day) and the other triiodothyronine (50 μ g/day, N=20). The add on medications were initiated at low dose and then titrated up to the final dose over a period of 4 weeks. The dose then remained the same till the end of the study. During the trial, the citalopram dose was kept unchanged at 40 mg/day. Lorazepam up to 4mg/day was permitted on an as required regime (prn) to tackle extreme agitation or insomnia during the first two weeks of the study. Four patients could not continue the trial because they developed side effects to nortriptyline (sedation, drowsiness and gastrointestinal upset). Three patients withdrew from the triiodothyronine group because of a worsening in their symptoms.

All subjects underwent a medical examination and a series of laboratory tests (blood count, fasting blood sugar, liver function tests, kidney function tests, thyroid function test and urine analysis) at base line. Vital signs and side effects to medications were monitored at base line, on weekly interval for the first 4 weeks and then at the end of the trial at 8th week.

A psychiatrist, using structured clinical interview for DSM-IV (SCID), interviewed the patients and their family at baseline and at the final visit. A single psychiatrist performed all ratings to reduce inter-rater error. In addition, patients along with their families completed a questionnaire providing information on demographic characteristics and past medical and drug histories. Depressive symptoms were evaluated by a psychologist using the 17-item Hamilton Rating Scale for Depression (HRSD-17) (17). A remission was defined as a score of 7 or

less on the HRSD-17. The primary outcome measure was baseline versus endpoint change in the HRSD-17 scores. Both the psychiatrist and the psychologist were blind to the treatment groups throughout the study period.

Statistical analysis:

We performed the statistical analysis on all patients including those who had dropped out. A t-test was used for comparisons of depression scores between groups. For all analyses, $p < 0.05$ was defined as statistically significant. All statistical analyses were performed using statistical package for social sciences (SPSS) version 11.

Results

Seven patients were dropped out of the study tolerability and adverse events are shown in table 2.

Table 2 . Tolerability and adverse events

	Nortriptyline group N=28	Triiodothyronine group N=20
Worsening of depression	0	3
Sedation and drowsiness	3	0
Gastrointestinal distress	1	0

There were no statistically significant differences between two groups regarding age, gender or educational level. The mean of baseline depression score was similar in both groups (table 1). However, a significant change in total mean scores was observed following treatment in both groups ($p < 0.05$) (table 3). The mean change of total depression score was greater in nortriptyline group compared to triiodothyronine group ($p < 0.05$).

Table 3 . Treatment outcomes

	Nortriptyline group N=24	Triiodothyronine group N=17
HRSD-17 remission rate at the end of study (%) *	33.33%	17.64%
HRSD-17 Scores at the end of study (\pm SD) *	7.3 \pm 5.70	11.45 \pm 4.55

*= $P < 0.005$

Discussion

Our study shows that the remission rate measured by a reduction in HRSD-17 scores was greater in nortriptyline group (33.33%) than triiodothyronine group (17.64%). Other studies shows the addition of triiodothyronine (T3) helps relieve depressive symptoms in non-hypothyroid major depressive disorder patients who failed to respond to an adequate course of standard SSRI antidepressant treatments(18). Hypothalamic-pituitary-thyroid axis (HPT) and L-triiodothyronine (L-T3) uptake into erythrocytes and membrane lipids have a role in the development and treatment of affective disorders. The change in the function of the membrane transporter for L-T3 in RBC in depression is probably connected with alteration of membrane fluidity and/or transporter-lipid interactions (19).

Other studies have shown that the addition of citalopram to nortriptyline led to clinical improvement (20,21). There is enough evidence that the antidepressant effects are mediated by both serotonin (5-HT) and norepinephrine (NE) (22). That is why in some studies, researchers have tried to augment the efficacy of SSRIs by adding an antipsychotic to the preexisting regime (23). Also serotonin-norepinephrine reuptake inhibitors (SNRIs) may be used as an alternative treatment for depressed patients who do not tolerate or respond adequately to treatment with a conventional antidepressant (24). Because the diffusion of NE may be spatially limited by serotonin transporters, the SSRIs, despite their selectivity, might enhance not only serotonergic but also noradrenergic neurotransmission, which might contribute to their antidepressant action (25). Furthermore, other studies show that NE plays an important role in mediating acute behavioral and neuro-chemical actions of many antidepressants, including most SSRIs (26) and use of nortriptyline might augment this process.

Our study has several limitations. Firstly, due to the relatively small sample size, the power of the study is limited. Secondly, there was no placebo control group in the study. In our study seven patients could not complete the trial due to the side effects. In addition, subjects were selected from academic

psychiatric outpatient clinics and may not be representative of community patients. Our study results cannot be generalized to patients with psychotic symptoms. Finally, we could not monitor the blood levels of the drugs due to financial restraints.

Acknowledgments

This study was supported by research committee of Mashad University of Medical Sciences. The authors would like to thank Dr Mahmood Reza Azarpazhooh and Dr Mohamad Taghi Shakeri for their invaluable support and collaboration.

References

1. Souche A, Montaldi S, Uehlinger C, Kasas A, Reymond MJ, Reymond P, et al. [Treatment of resistant depression with the citalopram-lithium combination. Methodology of a double-blind multicenter study and preliminary results]. *Encephale* 1991; 17(3): 213-9.
2. Carvalho AF, Nunes-Neto PR, Cavalcante JL, Oliveira Lima MC. Amisulpride augmentation after the failure of citalopram for depression: a case report. *J Clin Pharm Ther* 2007; 32(1): 97-9.
3. Agency for Health Care Policy and Research (AHCPR). Treatment of major depression. Rockville: The Agency; 1993 April. Publication No. 93-0551.
4. Greden JF. Recurrent depression- its overwhelming burden. In: Greden JF editor. Treatment of recurrent depression. Review of psychiatry. Washington DC: American Psychiatric Publishing; 2001; Vol.20. No.5. P.1-18.
5. Crismon ML, Trivedi M, Pigott TA, Rush, AJ, Hirschfeld RMA, Kahn DA, et al. The Texas medication algorithm project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. *J Clin Psychiatry* 1999; 60: 142-156.
6. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. *Psychiatr Clin North Am* 2003; 26: 457-494.
7. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. *Psychother Psychosom* (in press).
8. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. *Control Clin Trials* 2004; 25:119-142.
9. Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. *Arch Gen Psychiatry* 2004; 61: 669-680.
10. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. *N Engl J Med* 2006; 354: 1231-42.
11. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. *Arch Gen Psychiatry* 1993; 50: 387-93.
12. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ editors. *Psychopharmacology: fourth generation of progress*. New York: Raven Press 1995; 1081-97.
13. Rampello L, Alvano A, Chiechio S, Malaguarnera M, Raffaele R, Vecchio I, et al. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. *Neuropsychobiology* 2004; 50(4): 322-8.
14. Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. *J Clin Psychiatry* 2004; 65(3): 337-40.

15. Navarro V, Gasto C, Torres X, Marcos T, Pintor L. Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study. *Acta Psychiatr Scand* 2001; 103(6): 435-40.
16. Doggrell SA. After the failure of citalopram for depression, what next? *Expert Opin Pharmacother* 2006; 7(11): 1515-8.
17. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; 23: 56-62
18. Abraham G, Milev R, Stuart LJ. T3 augmentation of SSRI resistant depression. *J Affect Disord* 2006; 91(2-3): 211-5.
19. Kalisova-Starkova L, Fisar Z, Paclt I, Hanus Z, Vevera J. Red blood cell triiodothyronine uptake as membrane parameter of depression. *Physiol Res* 2006; 55(2): 195-204.
20. Baettig D, Bondolfi G, Montaldi S, Amey M, Baumann P. Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. *Eur J Clin Pharmacol* 1993; 44(4): 403-5.
21. Frahnert C, Rao ML, Grasmader K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. *J Chromatogr B Analyt Technol Biomed Life Sci* 2003; 794(1): 35-47.
22. Rantamaki T, Hendolin P, Kankaanpaa A, Mijatovic J, Piepponen P, Domenici E, et al. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase- C gamma signaling pathways in mouse brain. *Neuropsychopharmacology* 2007; Feb 21.
23. Huang M, Ichiwaka J, Li Z, Dai J, Meltzer HY. Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. *Psychopharmacology (Berl)* 2006; 185(3): 274-81.
24. Baldomero EB, Ubago JG, Cercos CL, Ruiloba JV, Calvo CG, Lopez RP. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. *Depress Anxiety* 2005; 22(2): 68-76.
25. Pistos C, Panderi I, tta-Politou J. Liquid chromatography-positive ion electrospray mass spectrometry method for the quantification of citalopram in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2004; 810(2): 235-44.
26. Cryan JF, O'leary OF, Jin SH, Friedland JC, Ouyang M, Hirsch BR, et al. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. *Proc Natl Acad Sci U S A* 2004; 101(21): 8186-91.